Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Chia-jen Liu, Irene M. Ghobrial, Mark Bustoros, Kaitlen Reyes, Kalvis Hornburg, Ashraf Z. Badros, James J. Vredenburgh, Adam Boruchov, Jeffrey V Matous, Aaron Caola, Bradley Rivotto, Alexandra Savell, Patrick Henrick, Claudia E. Paba-Prada, Robert L. Schlossman, Jacob Laubach, Jacalyn Rosenblatt, Andrew J Yee, Omar Nadeem, Rodrigo O. Maegawa, Andrzej Jakubowiak, Saad Z. Usmani, Manisha Bhutani, Joseph Cappuccio, Brianna Berrios, Kimberly Noonan, Oksana Zavidij, Tarek H Mouhieddine, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, Mairead Reidy, Jihye Park, Michael Agius, Mahshid Rahmat, Salomon Manier, Divaya Bhutani, Jeffrey A Zonder, Nikhil Munshi, Daniel Auclair, Kenneth Anderson, Paul Richardson
Institutions: Harvard University, Dana-Farber Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Duke University, Colorado Blood Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brown University, University of Chicago, University of Chicago Medical Center, Levine Cancer Institute, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Multiple Myeloma Research Foundation, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4229960078